Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 25;13(1):13.
doi: 10.1186/s13099-021-00409-5.

Ectopic gut colonization: a metagenomic study of the oral and gut microbiome in Crohn's disease

Affiliations

Ectopic gut colonization: a metagenomic study of the oral and gut microbiome in Crohn's disease

Shijia Hu et al. Gut Pathog. .

Abstract

Background: This study aims to characterize, the gut and oral microbiome in Asian subjects with Crohn's disease (CD) using whole genome shotgun sequencing, thereby allowing for strain-level comparison.

Methods: A case-control study with age, sex and ethnicity matched healthy controls was conducted. CD subjects were limited to well-controlled patients without oral manifestations. Fecal and saliva samples were collected for characterization of gut and oral microbiome respectively. Microbial DNA were extracted, libraries prepared and sequenced reads profiled. Taxonomic diversity, taxonomic association, strain typing and microbial gene pathway analyses were conducted.

Results: The study recruited 25 subjects with CD and 25 healthy controls. The oral microbe Streptococcus salivarius was found to be enriched and of concordant strains in the gut and oral microbiome of Crohn's disease subjects. This was more likely in CD subjects with higher Crohn's Disease Activity Index (184.3 ± 2.9 vs 67.1 ± 82.5, p = 0.012) and active disease status (Diarrhoea/abdominal pain/blood-in-stool/fever and fatigue) (p = 0.016). Gut species found to be significantly depleted in CD compared to control (Relative abundance: Median[Range]) include: Faecalibacterium prausnitzii (0.03[0.00-4.56] vs 13.69[5.32-18.71], p = 0.010), Roseburia inulinivorans (0.00[0.00-0.03] vs 0.21[0.01-0.53], p = 0.010) and Alistipes senegalensis (0.00[0.00-0.00] vs 0.00[0.00-0.02], p = 0.029). While Clostridium nexile (0.00[0.00-0.12] vs 0.00[0.00-0.00], p = 0.038) and Ruminococcus gnavus (0.43[0.02-0.33] vs 0.00[0.00-0.13], p = 0.043) were found to be enriched. C. nexile enrichment was not found in CD subjects of European descent. Microbial arginine (Linear-discriminant-analysis: 3.162, p = 0.001) and isoprene (Linear-discriminant-analysis: 3.058, p < 0.001) pathways were found at a higher relative abundance level in gut microbiome of Crohn's disease.

Conclusions: There was evidence of ectopic gut colonization by oral bacteria, especially during the active phase of CD. Previously studied gut microbial differences were detected, in addition to novel associations which could have resulted from geographical/ethnic differences to subjects of European descent. Differences in microbial pathways provide possible targets for microbiome modification.

Keywords: Crohn’s disease; Gastrointestinal microbiome; Metagenomics; Oral microbiome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Microbiome diversity at species level in Healthy (Control) vs Crohn’s Disease (CD). a Gut microbiome. b Salivary Microbiome
Fig. 2
Fig. 2
Gut microbiome species relative abundance in Healthy (Control) vs Crohn’s Disease (CD). a Faecalibacterium prausnitzii. b Roseburia inulinivorans. c Alistipes senegalensis. d Ruminococcus gnavus. e Clostridium nexile
Fig. 3
Fig. 3
Principal coordinate analysis of microbiome in Healthy (Control) vs Crohn’s Disease (CD). a Gut microbiome. b Salivary Microbiome. The arrows drawn are for the top 6 most significant species at p-value ≤ 0.0025
Fig. 4
Fig. 4
Phylogenetic tree plot of Streptococcus salivarius strain analysis for all Gut and Saliva samples

Similar articles

Cited by

References

    1. Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12(12):720–727. doi: 10.1038/nrgastro.2015.150. - DOI - PubMed
    1. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet. 2012;380(9853):1590–1605. doi: 10.1016/S0140-6736(12)60026-9. - DOI - PubMed
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–1913. doi: 10.1053/j.gastro.2008.09.012. - DOI - PMC - PubMed
    1. Cheifetz AS. Management of active Crohn disease. JAMA. 2013;309(20):2150–2158. doi: 10.1001/jama.2013.4466. - DOI - PMC - PubMed
    1. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54(2):237–241. doi: 10.1136/gut.2004.045294. - DOI - PMC - PubMed